Join
Live feed
·
PRReleasevia Quantisnow
Medicinova Inc logo

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

ByQuantisnow·Wall Street's wire, on your screen.
MNOV· Medicinova Inc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MNOV (Medicinova Inc) and more on Quantisnow.